GNLX | Genelux Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.1500 - 2.3100
52 Week Range	1.6000 - 16.60
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	62,996
Average Volume	156,436
Shares Outstanding	34,538,185
Market Cap	78,401,680
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-01-26

Valuation
Profitability
Growth
Health
P/E Ratio	-2.41
Forward P/E Ratio	N/A
EPS	-0.94
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	24
Country	USA
Website	GNLX

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

GNLX's peers: CING, CMRA, DYAI, MNPR, TERN, DAWN, ABOS, AMLX, MLTX, GLUE, NAMS, IVA, CGEM, CMPX, LRMR, IMRX, CNTA, CELC, IKNA, MAIA

*Chart delayed

Analyzing fundamentals for GNLX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see GNLX Fundamentals page.

Watching at GNLX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GNLX Technicals page.